Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-17

Study Completion Date

2023-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this protocol is to obtain a better match between the actual staging and the proposed treatment in order to avoid inadequate treatments at risk of complications. In patients with HCC classified as BCLC A to C, the combination of 18F-FDG and 18F-Fluorocholine PET- TomoDensitoMetry (TDM) with conventional imaging would clinically significantly modify the therapeutic strategy initially planned by conventional imaging alone. This change in therapeutic strategy would be from curative to palliative treatment or from loco-regional palliative to systemic palliative treatment. 18F-FDG and 18F-Fluorocholine PET-CT scans will be performed after inclusion of the patient in the study and prior to multidisciplinary consultation meeting for treatment discussion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma

NCT02824185

Patients Eligible to a Curative Treatment for Primary HCC

COMPLETED NA

Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

NCT02847468

Carcinoma, Hepatocellular

TERMINATED NA

Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma

NCT00915096

Lymphoma, Follicular

COMPLETED

Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers

NCT01421953

Lung Cancer Non-small-cell Lung Carcinoma

COMPLETED NA

18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma

NCT05871892

Hepatocellular Carcinoma

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer worldwide, developing on cirrhosis in 90% of cases. The prognosis of patients with HCC remains poor with an overall survival of around 10% at 5 years for all tumor stages combined. The diagnosis of HCC relies on non-invasive conventional imaging criteria (computed tomography \[CT\] and/or magnetic resonance imaging \[MRI\]) and/or histology. Conventional imaging (liver CT and/or MRI and lung CT) enables HCC staging according to the Barcelona Clinical Liver Cancer (BCLC) system, linking each stage to therapeutic modalities. Accurate staging with reliable imaging methods is therefore crucial to determine the best treatment strategy. The principal objective is to demonstrate that the identification of new tumor lesions by an experimental procedure combining 18F-FDG and 18F-Fluorocholine PET-CT scans in patients with HCC, modifies the initially planned therapeutic strategy of a curative treatment palliative treatment, from locoregional palliative treatment to systemic palliative treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single Group Assignment

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PET-TDM

PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine

Group Type EXPERIMENTAL

PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine

Intervention Type RADIATION

Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine

Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients\> 18 years old
* First diagnosis of HCC (no previous treatments received)
* Diagnosis of HCC according to The European Association for the Study of the Liver (EASL) 2012 criteria by "non-invasive" imaging on cirrhosis or by histology on cirrhosis or non-cirrhotic liver
* BCLC tumor stage A to C (excluding BCLC C with extrahepatic metastases) according to conventional imaging
* Will be able to have a PET scanner within 4 weeks after the inclusion visit
* Ability to stay 20 minutes longer for PET-CT scans
* Need for oral, intra-uterine or mechanical contraception for women of childbearing age
* Written consent for participation in the study
* Having medical insurance coverage

Exclusion Criteria

* Patients classified BCLC stage 0 (single HCC less than 2 cm)
* Patients classified as BCLC stage C with extrahepatic metastases
* Decreased cirrhosis (Child Pugh C) and / or patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 2 to 4 not candidates for liver transplantation
* Uncontrolled diabetes (defined by blood glucose\> 1.7 g / L at the time of inclusion)
* Hypersensitivity to 18F Fluorocholine or 18F-FDG or any of the excipients
* Creatinine clearance \<40 mL / min
* Contraindication to MRI: pacemaker or implantable cardiac defibrillator not compatible with MRI, neurostimulator, cochlear implant, intracerebral ferromagnetic vascular clip, intraocular or cerebral metallic foreign bodies, insulin pump
* Pregnant or lactating woman
* Patient under tutorship or curatorship or safeguard of justice
* Known allergy to iodine
* Patient deprived of liberty by judicial or administrative decision
* Patients with care "State Medical Aid"

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No